TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors

Dateline City: MALVERN, Pa. & KENILWORTH, N.J. MALVERN, Pa. & KENILWORTH, N.J.--(BUSINESS WIRE)--TetraLogic Pharmaceuticals Corporation (Nasdaq: TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today they have entered into an oncology clinical study collaboration. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orMerck Investor Relations:Justin Holko, 908-740-1879orTetraLogic Investor Relations:Pete A. Meyers, 610-889-9900, x103pete.meyers@tlog.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news